Section Chief's Welcome
The Section of Hematology/Oncology has a proud and long tradition of excellence in research-based patient care and clinical discovery. Ranked among the finest cancer programs in the country, the Section is comprised of nationally and internationally known faculty with expertise in all major types of malignancies, blood disorders, and experimental therapies. Major emphasis is given to translational research and the investigation of important laboratory observations in the clinic. One of the only institutions to have clinical trials in Phase I, II, and III of drug development, the distinguished faculty have ongoing investigations in each of these phases.
The Section has a very active research agenda as evidenced by our number of clinical trials and grants. Currently there are hundreds of clinical trials are available to patients with many open to enrollment. Many of these trials are available to patients with common malignancies such as leukemias, lymphomas, cancers of the lung, head and neck, breast, gastrointestinal tract, genitourinary tract, and other solid tumors. In addition, the Section has a large portfolio of grants, both federally and privately-funded, that support laboratory and translational investigations. A key initiative is to identify less toxic and more active treatment regimens and the potential identification of special patient populations that might benefit from these therapies.
The Section of Hematology/Oncology enthusiastically encourages you to learn more about our innovative programs that we offer for patients, trainees, and colleagues.